Delivering functional genes into cells to replace mutated genes, an approach known as gene therapy, holds potential for treating many types of diseases. The earliest efforts to deliver genes to diseased cells focused on DNA, but many scientists are now exploring the possibility of using RNA instead, which could offer improved safety and easier delivery.
MIT biological engineers have now devised a way to regulate the expression of RNA once it gets into cells, giving them precise control over the dose of protein that a patient receives. This technology could allow doctors to more accurately tailor treatment for individual patients, and it also offers a way to quickly turn the genes off, if necessary.
“We can control very discretely how different genes are expressed,” says Jacob Becraft, an MIT graduate student and one of the lead authors of the study, which appears in the Oct. 16 issue of Nature Chemical Biology. “Historically, gene therapies have encountered issues regarding safety, but with new advances in synthetic biology, we can create entirely new paradigms of ‘smart therapeutics’ that actively engage with the patient’s own cells to increase efficacy and safety.”
Becraft and his colleagues at MIT have started a company to further develop this approach, with an initial focus on cancer treatment. Tyler Wagner, a recent Boston University PhD recipient, is also a lead author of the paper. Tasuku Kitada, a former MIT postdoc, and Ron Weiss, an MIT professor of biological engineering and member of the Koch Institute, are senior authors.
Only a few gene therapies have been approved for human use so far, but scientists are working on and testing new gene therapy treatments for diseases such as sickle cell anemia, hemophilia, and congenital eye disease, among many others.
As a tool for gene therapy, DNA can be difficult to work with. When carried by synthetic nanoparticles, the particles must be delivered to the nucleus, which can be inefficient. Viruses are much more efficient for DNA delivery; however, they can be immunogenic, difficult, and expensive to produce, and often integrate their DNA into the cell’s own genome, limiting their applicability in genetic therapies.
Messenger RNA, or mRNA, offers a more direct, and nonpermanent, way to alter cells’ gene expression. In all living cells, mRNA carries copies of the information contained in DNA to cell organelles called ribosomes, which assemble the proteins encoded by genes. Therefore, by delivering mRNA encoding a particular gene, scientists can induce production of the desired protein without having to get genetic material into a cell’s nucleus or integrate it into the genome.
To help make RNA-based gene therapy more effective, the MIT team set out to precisely control the production of therapeutic proteins once the RNA gets inside cells. To do that, they decided to adapt synthetic biology principles, which allow for precise programming of synthetic DNA circuits, to RNA.
The researchers’ new circuits consist of a single strand of RNA that includes genes for the desired therapeutic proteins as well as genes for RNA-binding proteins, which control the expression of the therapeutic proteins.
“Due to the dynamic nature of replication, the circuits’ performance can be tuned to allow different proteins to express at different times, all from the same strand of RNA,” Becraft says.
This allows the researchers to turn on the circuits at the right time by using “small molecule” drugs that interact with RNA-binding proteins. When a drug such as doxycycline, which is already FDA-approved, is added to the cells, it can stabilize or destabilize the interaction between RNA and RNA-binding proteins, depending on how the circuit is designed. This interaction determines whether the proteins block RNA gene expression or not.
In a previous study, the researchers also showed that they could build cell-specificity into their circuits, so that the RNA only becomes active in the target cells.
The company that the researchers started, Strand Therapeutics, is now working on adapting this approach to cancer immunotherapy — a new treatment strategy that involves stimulating a patient’s own immune system to attack tumors.
Using RNA, the researchers plan to develop circuits that can selectively stimulate immune cells to attack tumors, making it possible to target tumor cells that have metastasized to difficult-to-access parts of the body. For example, it has proven difficult to target cancerous cells, such as lung lesions, with mRNA because of the risk of inflaming the lung tissue. Using RNA circuits, the researchers first deliver their therapy to targeted cancer cell types within the lung, and through their genetic circuitry, the RNA would activate T-cells that could treat the cancer’s metastases elsewhere in the body.
“The hope is to elicit an immune response which is able to pick up and treat the rest of the metastases throughout the body,” Becraft says. “If you’re able to treat one site of the cancer, then your immune system will take care of the rest, because you’ve now built an immune response against it.”
Using these kinds of RNA circuits, doctors would be able to adjust dosages based on how the patient is responding, the researchers say. The circuits also provide a quick way to turn off therapeutic protein production in cases where the patient’s immune system becomes overstimulated, which can be potentially fatal.
In the future, the researchers hope to develop more complex circuits that could be both diagnostic and therapeutic — first detecting a problem, such as a tumor, and then producing the appropriate drug.
The Latest on: RNA circuits
via Google News
The Latest on: RNA circuits
- Single-cell analysis uncovers fibroblast heterogeneity and criteria for fibroblast and mural cell identification and discriminationon August 7, 2020 at 2:09 am
To define and distinguish fibroblasts from vascular mural cells have remained challenging. Here, using single-cell RNA sequencing and tissue imaging, the authors provide a molecular basis for cell ...
- PTAB Decides Against Moderna in Challenge to Arbutus Vaccine Patenton August 5, 2020 at 9:16 am
As construed by the Board, the ‘196 publication discloses “using a small interfering RNA (siRNA) encapsulated in a serum stable ... or any other Federal Circuit decision we are aware of suggests that ...
- ‘Mulan’ Madness: With A Potential Disney+ Windfall, Will Studio Still Need Movie Theaters?on August 4, 2020 at 6:44 pm
Universal and AMC are looking like saints in the exhibition business right now after taking a kicking in the teeth by rival circuits for their controversial deal last week to crunch the theatrical ...
- Coronavirus Innovation Guideposts on the Eve of the COVID-19 Pandemicon July 30, 2020 at 12:05 pm
The causative agent of the outbreak was determined to be a coronavirus, an enveloped positive- and single-stranded RNA virus that infects vertebrates. The newly discovered coronavirus belongs to ...
- RNA biology provides the key to cell identity and healthon July 27, 2020 at 10:01 am
Two papers in Genome Research by the FANTOM Consortium have provided new insights into the core regulatory networks governing cell types in different vertebrate species, and the role of RNA as ...
- microRNA-93-5p promotes hepatocellular carcinoma progression via a microRNA-93-5p/MAP3K2/c-Jun positive feedback circuiton July 26, 2020 at 9:35 pm
However, the pathophysiologic relevance of miRNA-mediated RNA activation in hepatocellular carcinoma (HCC) remains to be established. Our previous miRNA expression profiling in seven-paired HCC ...
- RNA biology provides the key to cell identity and healthon July 26, 2020 at 5:00 pm
Thus, understanding how RNA is expressed is a key for grasping ... Sense–antisense miRNA pairs constitute an elaborate reciprocal regulatory circuit, Genome Research (2020).
- Huntington’s Disease Tied to Mitochondrial RNA Release, Innate Immune Activationon July 20, 2020 at 1:00 am
Though the mitochondrial RNA release discovery was the most striking ... including ones related to important neural functions such as their synapse circuit connections and circadian clock function.
- Neural vulnerability in Huntington's disease tied to release of mitochondrial RNAon July 17, 2020 at 9:57 am
In the first study to comprehensively track how different types of brain cells respond to the mutation that causes Huntington's disease (HD), MIT neuroscientists found that a significant cause of ...
via Bing News